New Therapy for Chronic Graft-Vs-Host Disease: Axatilimab
Axatilimab is a colony-stimulating factor-1 receptor–blocking monoclonal antibody indicated after 2 lines of systemic therapy.
Read More
Weekly Mim8 Effective in Pediatric Hemophilia A With and Without Inhibitors
February 21st 2025The new data demonstrates the effectiveness of Mim8 in children with hemophilia A regardless of inhibitor status, expanding the populations in which the novel drug in development could have a treatment benefit.
Read More